drugset / Trial / NCT05867420
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Phase 1/2
Recruiting
594 enrolled
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.
Timeline
- Start
- 2023-08-02
- Primary completion
- 2026-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASKG915 | Unknown | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Fruquintinib | Small molecule | 5 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |